Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series

Sami El-Dalati 1*, Sanjay Sridaran2, Marissa Uricchio3, Ellen G. Kline1 and Ryan Shields1

1Division of Infectious Diseases, Department of Internal Medicine, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA; 2Department of Internal Medicine, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA; 3Department of Pharmacy, University of Pittsburgh Medical Center, 3501 Terrace Street, Pittsburgh, PA 15213, USA

*Corresponding author. E-mail: s.eldalati10@gmail.com

Received 12 July 2021; accepted 2 September 2021

Background: Bloodstream infections caused by MSSA are associated with significant morbidity and mortality. Traditional treatment of MSSA bacteraemia includes an IV antistaphylococcal β-lactam and surgical source control when indicated.

Objectives: To evaluate the time to blood culture clearance as well as in-hospital and 90 day mortality in patients with persistent MSSA bacteraemia treated with combination antistaphylococcal penicillin plus carbapenem therapy.

Methods: Consecutive patients with persistent MSSA bacteraemia treated with combination therapy were identified by study investigators and reviewed by independent clinicians. The decision to initiate combination therapy was made by the consulting clinician or by the institution’s multidisciplinary endocarditis team.

Results: Among 10 patients with a median of 5 days of persistent MSSA bacteraemia, treatment with an antistaphylococcal penicillin plus carbapenem led to sterilization of blood cultures in all patients. Blood culture clearance occurred in a median of 1 day and patients received a median of 6 days of combination treatment. Four of seven patients who underwent source control of their primary site of infection cleared their bacteraemia on combination therapy prior to the surgical intervention. All patients survived to hospital discharge and 90 days post-discharge.

Conclusions: These data extend prior findings and provide further evidence that suggests the potential benefits of combination therapy among patients with persistent MSSA bacteraemia.

Introduction

Bloodstream infections caused by MSSA are associated with significant morbidity and mortality. One-third of patients develop invasive complications including septic arthritis, osteomyelitis, epidural abscesses and endocarditis. Mortality rates among those with endocarditis are as high as 40%. Traditional treatment of MSSA bacteraemia includes an IV antistaphylococcal β-lactam and surgical source control when indicated. Despite these measures, ~15% of patients experience persistent bloodstream infections for >7 days. Moreover, many patients are not candidates for surgical management of infectious complications. Thus, new therapeutic approaches against MSSA bacteraemia are needed to limit complications and lower mortality. Recent reports have documented encouraging outcomes for patients with persistent MSSA bacteraemia treated with cefazolin and ertapenem combination therapy. Here, we report our experience in managing 10 consecutive cases of MSSA bacteraemia treated with dual β-lactam combination therapy, prioritizing oxacillin in combination with a carbapenem.

Methods

Patient cases

Institutional review board exemption was obtained from the University of Pittsburgh and informed consent was not required of patients. Consecutive patients with persistent MSSA bacteraemia treated with combination therapy were identified by study investigators. Combination therapy was defined as the use of two antistaphylococcal β-lactams for ≥48 h as definitive treatment for MSSA bacteraemia. No patients who received β-lactam combination therapy were excluded over the study period. The decision to initiate combination therapy was made by the consulting clinician or by the
institution's multidisciplinary endocarditis team. All patients started on combination therapy had positive blood cultures upon treatment initiation. Patient charts were reviewed retrospectively by two independent investigators who were not involved in patient management.

**Definitions**

The duration of bacteremia was defined by the number of days that elapsed between the first positive blood culture and two consecutive negative blood cultures, or a single negative blood culture if only one was obtained. Days for which no blood cultures were collected were presumed positive unless there was a prior negative blood culture. Persistent bacteremia was defined as a positive follow-up blood culture collected ≥2 days after the first positive blood culture. Days to bacteremia clearance were defined by the number of days that elapsed between initiation of combination therapy and documentation of negative blood cultures. Patients without evidence of active infection 90 days after their index infection were presumed to be infection free.

**Antimicrobial susceptibility and synergy testing**

Index bloodstream isolates were collected and tested for susceptibility to oxacillin, etrapenem and meropenem by standard broth microdilution methods in duplicate. Sodium chloride was added to cation-adjusted Mueller–Hinton broth as recommended by CLSI. Staphylococcus aureus ATCC 29213 was used for quality control throughout; results were interpreted according to CLSI breakpoints. To identify in vitro synergy, oxacillin was tested in combination with etrapenem and meropenem by checkerboard assays. Synergy was defined as an FIC index ≤0.5 as previously described.7

**Results**

Between 17 August 2020 and 12 March 2021, 151 unique patients with S. aureus bacteremia were identified. Fifty-six percent (85/151) of patients were infected with MSSA. The overall median duration of MSSA bacteremia was 1 day (range: 1–11 days) and 27% (23/85) of cases met our criteria for persistent bacteremia. Overall, 10 cases of persistent MSSA bacteremia were treated with β-lactam combination therapy (Table 1). The median age was 32 years and 8 were women. Median Charlson Comorbidity Index and Pitt bacteremia scores were 1.5 (range: 1–4) and 0.5 (0–4), respectively. Seven cases were associated with infective endocarditis; six of which had vegetations identified by echocardiogram and one patient without a vegetation met modified Duke criteria for definite endocarditis (Case 9).11 Of the remaining cases, two were complicated by epidural abscesses and one by osteomyelitis and mediastinitis. Overall, seven patients were admitted to intensive care at the time of diagnosis.

All patients were initiated on in vitro active therapy (i.e. vancomycin) empirically within 15 h of index blood culture collection before de-escalation to a targeted antistaphylococcal β-lactam. Oxacillin was selected as initial MSSA-targeted therapy in nine cases. In total, patients received a median 3 days of targeted therapy prior to combination treatment. At the initiation of combination therapy, the median duration of bacteremia was 5 days (range: 3–8 days). Oxacillin plus etrapenem was started in seven cases. In the remaining three cases, cefazolin plus etrapenem was used in the setting of a penicillin allergy (Case 2), oxacillin was switched to nafcillin for a patient experiencing increased liver function tests (LFTs) prior to combination therapy (Case 6) and oxacillin plus meropenem was used for one patient with hypoalbuminemia (Case 8).12

Blood cultures were sterilized in all cases; six patients had documented clearance within 1 day and nine had documented clearance based on the first blood culture obtained following the initiation of combination therapy. Combination treatment was continued for a median of 6 days (range: 2–10 days) at which point carbapenems were discontinued in all cases. Source control was achieved in all three non-endocarditis cases by abscess drainage and debridement. In four of seven endocarditis cases, source control was achieved with valve repair/replacement. In four of seven patients who underwent definitive source control, blood cultures cleared on combination therapy prior to source control being achieved. Surgical valve cultures were collected in three patients and were positive for one (Case 8). All patients survived to hospital discharge. Two recurrent events were identified following discharge, including subsequent MSSA bacteremia in a patient with ongoing injection drug use (Case 3) and one patient with a persistent epidural abscess who received only 2 days of combination therapy (Case 6). All patients were alive at 90 days following the onset of MSSA bacteremia.

Overall, combination therapy was well tolerated. Following treatment initiation, three patients were switched from oxacillin to cefazolin due to increased LFTs, rash or to limit total parenteral volume. The median duration of antimicrobial therapy was 48 days. Rifampicin was added after carbapenems were discontinued in two patients with indwelling prosthetic material. MSSA isolates demonstrated median oxacillin, etrapenem and meropenem MICs of 0.5 (range: 0.25–1 mg/L), 0.25 (0.12–0.25 mg/L) and 0.25 (0.12–0.25 mg/L), respectively. One isolate showed in vitro synergy to the combination of oxacillin and etrapenem or meropenem. Additive activity (FIC index between 0.51 and 0.99) was confirmed for all other isolates. The median FIC index for oxacillin plus etrapenem or meropenem was 0.61 and 0.66, respectively.

**Discussion**

In this case series we report our experience in successfully managing 10 consecutive patients with persistent MSSA bacteremia who were treated with combination β-lactam therapy. Combination treatment was initiated following a median of 5 days of persistent bacteremia and repeat blood cultures cleared in all patients at a median of 1 day. All patients survived to our long-term follow-up endpoint of 90 days and recurrent infections were infrequent. Seven of 10 patients had definite endocarditis.11 MSSA was not cultured from the excised valve/vegetations in two of three patients who underwent valve surgery, which allowed for shorter durations of antibiotic therapy post-operatively. Importantly, decisions regarding initiating dual β-lactam therapy for endocarditis patients were made by a multidisciplinary endocarditis team.13 Taken together, our data extend those recently presented by Ulloa and colleagues7 who showed positive clinical outcomes among 11 patients with persistent MSSA bacteremia treated with cefazolin and etrapenem. Here, oxacillin plus a carbapenem was prioritized, suggesting that combination β-lactam therapy can be successfully employed with either an antistaphylococcal penicillin or cefazolin in combination with etrapenem. These new insights are noteworthy given the association between...
| Case | Age/Sex | Comorbidities | CCI | ICU | PBS | Source(s) of BSI (size of vegetation) | Tx (duration, days) | Duration of BSI (days) | Source control (duration of BSI afterwards, days) | Definitive Tx (total duration, days) | Clinical outcome and comments |
|------|---------|---------------|-----|-----|-----|--------------------------------------|---------------------|------------------------|-----------------------------------------------|------------------------------------|----------------------------------|
| 1    | 32/F    | HCV, PWID     | 1   | Yes | 1   | Native TV IE (1.4 x 2.6 cm)          | FEP (2) VAN (3) OXA (4) OXA + ETP (5) 6 1 | TV repair on hospital Day 6 (2) | OXA (34)                         | Survived to hospital discharge and infection free at Day 90. |
| 2    | 23/F    | HCV, PWID, bipolar disorder | 1  | No  | 0   | Native TV IE (2.7 cm)                | FEP (3) VAN (3) CFZ (1) CFZ + ETP (9) 3 2 | TV repair on hospital Day 9 (N/A; cleared on combo therapy) | CFZ (32)                         | Survived to hospital discharge and infection free at Day 90. |
| 3    | 32/M    | HCV, PWID     | 1   | Yes | 2   | Prosthetic TV IE (1.1 x 1.3 cm)      | TZP (1) VAN (1) OXA (3) OXA + ETP (9) 5 1 | None                                  | OXA (47)                         | Survived to hospital discharge. Developed recurrent MSSA IE 32 days after discharge in the setting of ongoing injection drug use. |
| 4    | 26/F    | HCV, PWID, preeclampsia, asthma | 1  | No  | 0   | Native PV IE (2.4 x 0.9 cm)          | N/A OXA (3) OXA + ETP (5) 3 6 1 | None                                  | OXA (11), then CFZ (46)           | Survived to hospital discharge and infection free at Day 90. Switched from OXA to CFZ due to increasing LFTs. |
| 5    | 28/F    | HCV, PWID, PUD, depression | 2   | Yes | 0   | Native MV and TV IE (1.6 x 1.3 cm) (1.2 x 2.1 cm) | MEM (1) VAN (3) OXA (3) OXA + ETP (10) 5 2 | MV and TV replacement on hospital Day 25 (N/A; cleared on combo therapy) | OXA (49)                         | Survived to hospital discharge and infection free at Day 90. Course complicated by mycotic aneurysm and septic emboli. |
| 6    | 64/F    | HTN, RA, T2DM | 4   | Yes | 3   | Epidural abscess, septic arthritis   | FEP (2) VAN (3) OXA (3), then NAF (4) NAF + ETP (2) 8 3 | Piriformis abscess drainage on hospital Day 29 Anterior lumbar debridement on hospital Day 32 Hardware removal and posterior lumbar debridement on hospital Day 35 (N/A; cleared on combo therapy) | OXA (3), then NAF (42), then CFZ (18) RIF (28) | Survived to hospital discharge. Developed recurrent epidural abscess 21 days after discharge. Switched from OXA due to CFZ due to increasing LFTs. |
| 7    | 70/F    | HLD, Afib     | 3   | Yes | 1   | Vertebral OM, mediastinitis          | TZP (2) VAN (2) OXA (2) OXA + ETP (6) 4 1 | Mediastinal abscess drainage on hospital Day 2 (4) | OXA (11), then TZP (8), then OXA (59) | Survived to hospital discharge and infection free at Day 90. Transitioned to TZP to treat concurrent pneumonia. |
| 8    | 22/F    | PWID, T1DM    | 1   | Yes | 0   | Native TV IE (3.0 x 2.5 cm)          | TZP (3) VAN (3) OXA (1) OXA + MEM (4), then CFZ + MEM (4) 6 2 | TV replacement on hospital Day 4 (1) | OXA (5), then CFZ (42) | Survived to hospital discharge and infection free at Day 90. Course complicated by septic emboli. Switched from OXA to CFZ due to volume status concerns. |
| 9    | 47/M    | HTN, HLD, T2DM, CVA | 2  | Yes | 4   | Native MV IE                         | VAN (1) OXA (1) OXA + ETP (6) 3 1 | None                                  | OXA (10), then CFZ (35)          | Survived to hospital discharge and infection free at Day 90. |
| Case | Age/Sex | Comorbidities | CCI | ICU | PBS | Source(s) of BSI (size of vegetation) | Tx (duration, days) | Duration of BSI (days) | Source control (duration of BSI afterwards, days) | Definitive Tx (total duration, days) | Clinical outcome and comments |
|------|---------|---------------|-----|-----|-----|-------------------------------------|---------------------|------------------------|-----------------------------------------------|-------------------------------------|-------------------------------|
|      |         |               |     |     |     | empirical                           | targeted            | combo                  |                                               |                                     |                                |
| 10   | 66/F    | HTN, HLD, T2DM | 3   | No  | 0   | Epidural abscess                    | FEP (2)             | VAN (2)                | OXA (3)                                      | OXA (49)                            | Survived to hospital discharge and infection free at day 90. |

Afib, atrial fibrillation; BSI, bloodstream infection; CCI, Charlson Comorbidity Index; CFZ, cefazolin; CVA, cerebrovascular accident; ETP, ertapenem; FEP, cefepime; HLD, hyperlipidaemia; HTN, hypertension; IE, infective endocarditis; MEM, meropenem; MV, mitral valve; N/A, not applicable; NAF, nafcillin; OM, osteomyelitis; OXA, oxacillin; PBS, Pitt bacteraemia score; PUD, peptic ulcer disease; RIF, rifampicin; TZP, piperacillin/tazobactam; PWID, person who injects drugs; PV, pulmonary valve; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TV, tricuspid valve; Tx, treatment; VAN, vancomycin.

*At the time of diagnosis of bloodstream infection.

*No blood cultures drawn on the day after combination treatment was initiated.

*Rifampicin added after ertapenem was discontinued.

*Patient was already known to have MSSA bacteraemia and had left against medical advice 1 week prior to returning to the hospital for further care. The start date of BSI in this case refers to first positive culture after returning for care and not to when cultures were initially positive during the first hospitalization.

*No blood cultures drawn until 2 days after combination treatment was initiated.
Oxacillin and ertapenem for persistent MSSA bacteraemia

Transparency declarations

All authors contributed to the manuscript and have no conflicts of interest to disclose.

References

1. Hidalgo-Tenorio C, Gómez J, Martínez-Marcos FJ et al. Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis. BMC Infect Dis 2020; 20: 160.
2. del Rio A, Cervera C, Moreno A et al. Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis 2009; 48 Suppl 4: S246–53.
3. Ringberg H, Thorén A, Lilja B. Metastatic complications of Staphylococcus aureus septicaemia. To seek is to find. Infection 2000; 28: 132–6.
4. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82: 333–9.
5. Gentry CA, Rodvold KA, Novak RM et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17: 990–7.
6. Chong YP, Park SJ, Kim HS et al. Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore) 2013; 92: 98–108.
7. Ulloa ER, Singh KV, Geriak M et al. Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2020; 71: 1413–8.
8. Khalit B, Johnson LB, Sharma M et al. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009; 41: 4–9.
9. Akers SM, Kinney K, Butcher MI et al. Clearance of persistent Staphylococcus aureus bacteremia in a preterm neonate with the use of combination cefazolin and ertapenem. J Pediatr Pharmacol Ther 2020; 25: 54–7.
10. Kuehl R, Morata L, Boeig C et al.; International Staphylococcus aureus collaboration study group and the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis 2020; 20: 1409–17.
11. Li J, Sexton D, Mick N et al. Proposed modifications to the Duke Criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633–8.
12. Zusman O, Farbman L, Tredler Z et al. Association between hypoalbuminaemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study. Clin Microbiol Infect 2015; 21: 54–8.
13. Botelho-Nevers E, Thuny F, Casalta JP et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med 2009; 169: 1290–8.
14. Miller WR, Seas C, Carvajal LP et al. The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia. Open Forum Infect Dis 2018; 5: ofy123.
15. Li J, Echevarria KL, Hughes DW et al. Comparison of cefazolin versus oxacillin for treatment of complicated bacteraemia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58: 5117–24.
16. Grill MF, Maganti RK. Neuromotor effects associated with antibiotic use: management considerations. Br J Clin Pharmacol 2011; 72: 381–93.
17. Dumitrascu O, Choudhury P, Boisset S et al. β-lactams interfering with PBPs induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 3261–71.

Funding

The study was carried out as part of our routine work.